← Leaderboards
Nouri Neamati
University Of Miami School Of Medicine
$15,871,783
Attributed
$22,561,259
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.2M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,561,259 · 13
By mechanism
R01$16,437,745 · 8
U01$4,208,845 · 1
P01$958,480 · 1
R21$915,439 · 2
R03$40,750 · 1
Top collaborators
- Mats Ljungman5 shared
- Alnawaz Rehemtulla5 shared
- Vaibhav Sahai5 shared
- Yu Leo Lei4 shared
- David Benner Lombard4 shared
- Sita Reddy4 shared
- John Chadwick Brenner3 shared
- Lucio Comai3 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- William Scott$7,845,701
- Phillip Ruiz$453,309
- Izidore S Lossos$4,248,673
- Deborah Mash$2,882,403
- Brandon Strickland$3,471,553
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoToxic EffectCancer CellTumorMediatingPathway InteractionsMalignant NeoplasmsLeadGenesSmall MoleculeIn VitroPharmaceutical PreparationsTherapeutic TargetXenograft ModelCell LineChemotherapyDrug ResistanceTumor GrowthDesignBaseInnovationInhibitor/AntagonistCancer Therapy
Grant awards (55)
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer$1,084,396
R01 · FY2025 · CA · contact PI
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer$472,491
R01 · FY2025 · CA · contact PI
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma$1
R01 · FY2025 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer$515,091
R01 · FY2024 · CA · contact PI
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma$489,139
R01 · FY2024 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer$449,119
R01 · FY2024 · CA · contact PI
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer$531,356
R01 · FY2023 · CA · contact PI
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma$518,307
R01 · FY2023 · CA
Targeting the RNA Exosome for Cancer Therapeutics$479,616
R01 · FY2023 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer$463,556
R01 · FY2023 · CA · contact PI
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer$542,198
R01 · FY2022 · CA · contact PI
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma$528,886
R01 · FY2022 · CA
Targeting the RNA Exosome for Cancer Therapeutics$479,616
R01 · FY2022 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer$473,270
R01 · FY2022 · CA · contact PI
Targeting the RNA Exosome for Cancer Therapeutics$489,405
R01 · FY2021 · CA
Enhance Immunoprevention by Blocking Early Expansion of Suppressive Myeloid Cells - Supplement Proposal$250,000
U01 · FY2021 · DE
Robust Immuno-prevention Strategies for High-Risk Oral Epithelial Dysplasia$158,870
U01 · FY2021 · DE
ROS-targeted therapy for pancreatic cancer$562,471
R01 · FY2020 · CA · contact PI
Targeting the RNA Exosome for Cancer Therapeutics$489,405
R01 · FY2020 · CA
gp130 as a novel therapeutic target in ovarian cancer$365,029
R01 · FY2020 · CA · contact PI
Robust Immuno-prevention Strategies for High-Risk Oral Epithelial Dysplasia$3,595,405
U01 · FY2019 · DE
Targeting the RNA Exosome for Cancer Therapeutics$489,405
R01 · FY2019 · CA
ROS-targeted therapy for pancreatic cancer$470,257
R01 · FY2019 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$459,059
R01 · FY2019 · CA · contact PI
Robust immunoprevention strategies for high-risk oral epithelial dysplasia$204,570
U01 · FY2019 · DE
gp130 as a novel therapeutic target in ovarian cancer$1
R01 · FY2019 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$483,547
R01 · FY2018 · CA · contact PI
gp130 as a novel therapeutic target in ovarian cancer$376,320
R01 · FY2018 · CA · contact PI
ROS-targeted therapy for pancreatic cancer - Diversity Supplement$75,339
R01 · FY2018 · CA · contact PI
ROS-targeted therapy for pancreatic cancer$1
R01 · FY2018 · CA · contact PI
ROS-targeted therapy for pancreatic cancer$562,471
R01 · FY2017 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$486,120
R01 · FY2017 · CA · contact PI
gp130 as a novel therapeutic target in ovarian cancer$376,320
R01 · FY2017 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$486,120
R01 · FY2016 · CA · contact PI
ROS-targeted therapy for pancreatic cancer$460,974
R01 · FY2016 · CA · contact PI
gp130 as a novel therapeutic target in ovarian cancer$376,320
R01 · FY2016 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$486,251
R01 · FY2015 · CA · contact PI
ROS-targeted therapy for pancreatic cancer$460,974
R01 · FY2015 · CA · contact PI
gp130 as a novel therapeutic target in ovarian cancer$376,907
R01 · FY2015 · CA · contact PI
Identification of Therapeutic Small Molecules for Myotonic Dystrophy Type 1$15,680
R21 · FY2013 · NS
Identification of Therapeutic Small Molecules for Myotonic Dystrophy Type 1$205,000
R21 · FY2012 · NS
Identification of Therapeutic Small Molecules for Myotonic Dystrophy Type 1$244,750
R21 · FY2011 · NS
Integrin avb3 targeted drug design, delivery, and imaging$206,889
R01 · FY2011 · CA · contact PI
High Throughput Screen for Myotonic Dystrophy Type 1$40,750
R03 · FY2011 · MH
CORE--ANALYTIC$213,293
P01 · FY2010 · AG · contact PI
Integrin avb3 targeted drug design, delivery, and imaging$213,288
R01 · FY2010 · CA · contact PI
Inhibition of HIV-1 Integrase-LEDGF/P75 Interactions$204,000
R21 · FY2010 · AI · contact PI
Inhibition of HIV-1 Integrase-LEDGF/P75 Interactions$246,009
R21 · FY2009 · AI · contact PI
Integrin avb3 targeted drug design, delivery, and imaging$213,984
R01 · FY2009 · CA · contact PI
CORE--ANALYTIC$209,308
P01 · FY2009 · AG · contact PI
Integrin avb3 targeted drug design, delivery, and imaging$214,048
R01 · FY2008 · CA · contact PI
CORE--ANALYTIC$203,705
P01 · FY2008 · AG · contact PI
Integrin avb3 targeted drug design, delivery, and imaging$229,798
R01 · FY2007 · CA · contact PI
CORE--ANALYTIC$201,806
P01 · FY2007 · AG · contact PI
CORE--ANALYTIC$130,368
P01 · FY2006 · AG · contact PI